IL-32 mRNA Expression of Bone Marrow Stromal Cells and Its Correlation with Cell Apoptosis in Patients with Myelodysplastic Syndrome / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To investigate the IL-32 mRNA expression of bone marrow stromal cells and its correlation with apoptosis of bone marrow mononuclear cells in patients with myelodysplastic syndrome (MDS).</p><p><b>METHODS</b>Bone marrow samples from 26 MDS patients and 10 iron deficiency anemia (IDA, as control) patients were collected, RT-PCR was used to detect the IL-32 mRNA expression of bone marrow stromal cells, and the apoptosis of bone marrow mononuclear cells was detected by flow cytometry with Annexin V-FITC/PI dowble staining. The born marrow lymphocytes and NK cells were detected by means of direct immunofluorescence labeling whole blood hemolysis and flow cytometry.</p><p><b>RESULTS</b>IL-32 mRNA expression of bone marrow stromal cells in the MDS patients was significantly higher than that of control group, the IL-32 mRNA expression of bone marrow stromal cells in patients with RA, RAS and RCMD was significantly higher than that in patients with RAEB. There was no obvious difference between RAEB and the control groups. The apoptosis of bone marrow mononuclear cells in MDS group was significantly higher than that in the control group, the apoptosis of bone marrow mononuclear cells in patients with RA, RAS and RCMD was significantly higher than that in RAEB. There was no significant difference between RAEB group and control group. The IL-32 mRNA expression in bone marrow stromal cells significantly correlated with the apoptosis of bone marrow mononuclear cells in MDS patients. The NK cell number in born marrow of MDS patients and the control group had no significant difference.</p><p><b>CONCLUSION</b>The expression of IL-32 mRNA in bone marrow stromal cells significantly relates with the apoptosis of MDS cells, and the secretion of IL-32 by bone marrow stromal cells may be one of the reasons for the apoptosis of MDS bone marrow cells. It is speculated that the abnormal MDS bone marrow microenvironment is involved in the apoptosis of bone marrow cells.</p>

Mutation detection of mitochondrial DNA D-loop region in bone marrow cells of acute leukemia / 中国实验血液学杂志

This study was aimed to detect the mutations and microsatellite instability (mtMSI) in mitochondrial DNA (mtDNA) D-loop region in bone marrow cells of acute leukemia (AL) patients, and to analyze their relationship with the pathogenesis of AL. 19 cases of newly diagnosed AL were enrolled in this study. Through extracting mtDNA, the D-loop region was amplified by polymerase chain reaction (PCR), the sequences of PCR products were detected by the pros- and cons-direct sequencing methods. The sequencing results were compared with the revised Cambridge reference sequence (rCRS) and the relevant database (MITOMAP database, GenBank database, mtDB database). The results showed that the mutation rate of mtDNA D-loop region in AL was 79% (15/19). 215 variations (35 mutations, 180 SNP) and a kind of mtMSI in the D-loop region were detected. A new type of mutation nt150 C-CT was found. Also, there was no significant difference in the number of mutations between patients with different ages and different types of AL (AML, B-ALL). It is concluded that there is high frequency of mutations in the mtDNA D-loop, and the mutations may be associated with the pathogenesis of AL.

Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To compare the curative effect, safety and survival of Nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced NSCLC.</p><p><b>METHODS</b>From Sep 2005 to Mar 2009, fifty-eight patients with NSCLC treated in the Shanghai Chest Hospital who failed first-line chemotherapy and receiving docetaxel or docetaxel combined with nedaplatin were retrospectively analyzed. Survival analysis was evaluated by Kaplan-Meier and Log-Rank test. There were 20 patients in the combination group, and 38 in the single-agent group.</p><p><b>RESULTS</b>The PFS was 4.35 months for combination group and 4.0 months for single-agent group, there was a significant difference between the two groups (P < 0.05). The mean survival time and 1-year survival rate were 13.5 months vs. 10.6 months and 29.0% vs. 22.0%, respectively, with no significant difference. The Hematological toxicity in the combination group was higher than that in the single-agent group, 15.0% vs. 10.5% (P = 0.003), and no renal toxicity was noted in this study.</p><p><b>CONCLUSIONS</b>Compared with the treatment with docetaxel alone, Nedaplatin combined with docetaxel as a second line treatment for NSCLC has a better curative effect and acceptable toxicity.</p>

Effect of anemia on prognosis of non-small cell lung cancer patients / 肿瘤

Objectives: To investigate the correlation of the hemoglobin levels with prognosis of non-small cell lung cancer (NSCLC) patients. Methods: The clinical data from 500 patients with NSCLC who were admitted in the Shanghai Chest Hospital from November 2003 to March 2005 were retrospectively analyzed. Statistical difference was analyzed by χ2 test. Survival analysis was evaluated by Kaplan-Meier and log-rank test. Multivariate analysis was performed by COX stepwise regression model. The hemoglobin levels were obtained at the initial visit to the hospital. Anemia is defined as a hemoglobin level <120 g/ L in men and <110 g/L in women. Results: The median survival time for all the 500 patients was 27.17 months, 1-year survival rate was 73.4%. Among them, 147 (29.4%) patients had anemia and 353(70.6%) patients without anemia. The incidence of anemia was higher in those patients who received chemotherapy. After the four-cycle chemotherapy, the proportion of patients experiencing anemia was 84.3%. The median survival time was 21.38 months for the patients with anemia and 30.82 months for patients without anemia. The 1-year survival rate was significantly lower in patients with anemia than those without anemia (64.3% vs 76.8%, P = 0.028). Anemia had significant influence on the survival time of female patients (P = 0.049). There was significant difference in the survival time between III stage patients with and without anemia (P = 0.035). Anemia had no significant effect on the survival of NSCLC patients at stages I, II, and IV. The COX stepwise regression analysis showed that anemia, sex, pathological classification, clinical stage, liver function, and surgical resection were independent prognostic factors for the NSCLC patients. Conclusion: Anemia determined by primary diagnosis was related with the survival time of NSCLC patients. Anemia is an independent prognostic factor for NSCLC patients.